dexamethasone sodium phosphate + levofloxacin hemihydrate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
dexamethasone sodium phosphate + levofloxacin hemihydrate: clinical details
Prescribing considerations
- Licensed only for adults in association with cataract surgery; paediatric safety and efficacy have not been established.
- Use cautiously in renal or hepatic impairment because the combination has not been studied in these groups.
- Consider resistant or non-susceptible organisms if infection develops.
- Exercise caution in diabetes, glaucoma, previous steroid-induced ocular hypertension, dry eye, compromised cornea, or corneal or scleral thinning.
- Benzalkonium chloride may irritate dry or damaged eyes; phosphate may rarely cause corneal calcification in markedly damaged corneas.
Contraindications and cautions
- Hypersensitivity to levofloxacin, another quinolone, dexamethasone, another corticosteroid or an excipient
- Herpes simplex keratitis, varicella or another viral disease of the cornea or conjunctiva
- Mycobacterial eye infection
- Fungal disease of ocular structures
- Untreated purulent eye infection
Monitoring
- Monitor intraocular pressure, particularly with glaucoma, diabetes or previous steroid-related pressure elevation.
- Assess persistent blurred vision or other visual disturbance.
- Monitor corneal healing when ocular NSAIDs are used or corneal integrity is impaired.
- Reassess for secondary bacterial, viral or fungal infection if symptoms worsen or prolonged exposure is necessary.
- Monitor for systemic corticosteroid effects in predisposed patients or those taking strong CYP3A4 inhibitors.
Clinical pharmacology
Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV. Dexamethasone suppresses inflammatory pathways and inflammatory-cell migration. Ocular administration produces high local tissue concentrations with substantially lower systemic exposure.
Formulation and product differences
- Preserved multidose ophthalmic solution containing benzalkonium chloride and phosphate buffer.
- Supplied in a 5 mL low-density polyethylene bottle with a dropper tip.
- The solution is clear and greenish-yellow in the bottle; expelled drops appear clear and colourless.
- Discard the bottle 28 days after first opening.
dexamethasone sodium phosphate + levofloxacin hemihydrate preparations and strengths
Eye drops
Route: Ophthalmic
Strengths: 1 mg/mL + 5 mg/mL
dexamethasone sodium phosphate + levofloxacin hemihydrate interactions
Systemic interactions are generally unlikely after use in the eye, but some combinations require attention.
Topical ocular NSAIDs
Combined use with an ocular corticosteroid may increase the risk of delayed corneal healing.
Ritonavir or cobicistat
These may reduce dexamethasone clearance and increase systemic corticosteroid effects. Avoid unless the benefit outweighs the risk and monitor when necessary.
Other eye drops or ointments
Apply eye ointments last.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.